Navigation Links
Scott Glenn Joins Exagen Diagnostics as Chairman and CEO
Date:12/1/2009

ALBUQUERQUE, N.M., Dec. 1 /PRNewswire/ -- Exagen Diagnostics, Inc., a molecular diagnostics laboratory that discovers, develops and markets proprietary genomic tests, today announced the appointment of Scott Glenn as chairman of the company's board of directors and chief executive officer.

Prior to joining Exagen, Glenn was managing partner of Windamere Venture Partners and founder of a number of successful biomedical companies including Prometheus Laboratories, Santarus, Dexcom, Somaxon Pharmaceutical and Cadence Pharmaceuticals. In addition, he was a founder at Zogenix, NovaCardia (sold to Merck) and Proprius (sold to Cypress). Prior to Windamere Ventures, he was the president and CEO of Quidel Corporation and before that he held various management positions, including division general manager with Allergan Pharmaceuticals. He serves as a director and founder of Evoke Pharmaceuticals and Planet Biopharmaceuticals.

"I am impressed with Exagen's unique position and approach to managing the massive amounts of genetic information created in the past decade, developing it into superior molecular diagnostics for use in a large number of diseases," said Glenn. Coperna, Exagen's search engine, is differentiated from competing methodologies because it can quickly analyze a broad amount of genomic information and identify statistically significant marker sets without the need for lengthy laboratory testing processes. This results in dramatic "speed to discovery" advantages for Exagen.

About Exagen

Exagen is the emerging leader in laboratory-discovered and developed genomic tests specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. Using Coperna, the company's proprietary, algorithm-driven computational tool and search engine that runs on high-performance computational clusters, it combines the ability to process massive amounts of data contained in genomic datasets with intelligent, rapid search methods. Coperna's targeted and precise discovery model has no conventional equivalent in the molecular diagnostics industry as it can identify relevant marker sets with superior sensitivity and specificity relative to markers identified via traditional analytical methods. For more information, visit www.exagen.com.

SOURCE Exagen Diagnostics, Inc.


'/>"/>
SOURCE Exagen Diagnostics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Ancestry.com DNA Testing Reveals Roots Authors Scottish Ancestry
2. Scottsdale Facility to Be First in U.S. to Showcase True REST Technology
3. Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine
4. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
5. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
6. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
7. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
8. Actress and Mother Jennifer Garner Joins American Lung Association to Encourage Americans to Get an Influenza Vaccination
9. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
10. Olympic Gold Medalist Kristi Yamaguchi Joins American Lung Association of Michigan to Address Seriously Low Vaccination Rates; Urge Metro-Detroiters to Get Immunized This Season
11. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 26, 2016 One of Australia,s ... formation of a new biotechnology company, Noxopharm Limited [ABN 50 608 ... IPO and to list on the ASX. Noxopharm is ... to enter a Phase 1 clinical study later this year. ... one of the biggest problems facing cancer patients - the ability ...
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/26/2016)... 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) ... measures required to build a strong and stable market ... listed on the OTC Markets-pink current trading platform. ... "We are seeing an anomaly in market trading activities ... by the Company, but shareholders and market players as ...
Breaking Medicine Technology:
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... College District , the only authorized OSHA Training Institute Education Center headquartered in ... by protecting their workers from extreme heat at their worksites. Employers with ...
(Date:6/27/2016)... ... 2016 , ... "FCPX editors can now reveal their media with growing colorful ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings the ... can now reveal the media of their split screens with growing colorful panels. , ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... its affiliation with Tennessee Counseling Association. This new relationship allows TherapySites ... Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely ...
(Date:6/27/2016)... ... June 27, 2016 , ... ePAY ... partnership with Connance, a healthcare industry leader providing predictive analytics to optimize ... combine to provide health systems, hospitals and ambulatory surgical centers with dramatic ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... to revolutionize the emergency ambulance transport experience for the millions of people who ... Uber has disrupted the taxi industry through the use of technology. Now, SmartEMS ...
Breaking Medicine News(10 mins):